Real-life experience in Brazil in patients with castration-resistant prostate cancer treated with Olaparib+Abiraterone

Trial Identifier: D0817R00083
Sponsor: AstraZeneca
Start Date: January 2025
Primary Completion Date: February 2025
Study Completion Date: February 2025
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Brazil, Bahia Salvador, Bahia, Brazil, 41950640
Brazil, Rio Grande do Norte Natal, Rio Grande do Norte, Brazil, 59062-000
Brazil, Rio Grande do Sul Santa Maria, Rio Grande do Sul, Brazil, 97015-450
Brazil, São Paulo São Paulo, Brazil, 05652900
Brazil, São Paulo São Paulo, Brazil, 01327-001